Morgan Stanley Sees 2015 Numbers Going Higher for Abbott Laboratories

In a report published Thursday, Morgan Stanley analyst David R. Lewis reiterated an Overweight rating and $45.00 price target on

. In the report, Morgan Stanley noted, “Accelerating 2H14 leverage was overlooked post underwhelming 1Q guidance. Our EBIT analysis and management's focus on corporate costs imply consensus is materially below our 2015 EPS. We outline a case for mid-teens '15-'16 EPS growth and see >5%+ upside to 2015 consensus numbers. Reiterate OW.” Abbott Laboratories closed on Wednesday at $39.79.